Avedro Welcomes Robert J. Palmisano to its Board of Directors

Avedro Welcomes Robert J. Palmisano to its Board of Directors

May 14, 2014

Seasoned Veteran in Value Creation for Ophthalmic Medical Device Companies

Receptos Reports First Quarter 2014 Financial Results

Receptos Reports First Quarter 2014 Financial Results

May 12, 2014

- Top-line results of Phase 2 trial of RPC1063 in relapsing multiple sclerosis expected in mid-2014 -

- Phase 3 trial of RPC1063 in relapsing multiple sclerosis enrolling patients globally -

- Results of Phase 2 trial of RPC1063 in ulcerative colitis expected in Q4 2014 - 

SAN DIEGO, May 12, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. today provided development program updates and announced financial results for the first quarter ended March 31, 2014.

BIND Therapeutics Reports First Quarter 2014 Financial Results and Updates BIND-014 Clinical Development Plan

BIND Therapeutics Reports First Quarter 2014 Financial Results and Updates BIND-014 Clinical Development Plan

May 8, 2014

- BIND to expand trial program to evaluate BIND-014 in NSCLC with KRAS mutations -

Agios Pharmaceuticals Reports First Quarter 2014 Financial Results

Agios Pharmaceuticals Reports First Quarter 2014 Financial Results

May 8, 2014

AG-221 Showed Promising Clinical Activity in AML; Additional Data to be Presented at EHA

Three First-in-Class Compounds now in Clinical Development

CAMBRIDGE, Mass., May 08, 2014 (BUSINESS WIRE) -- Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and inborn errors of metabolism (IEMs), today reported business highlights and financial results for the first quarter ended March 31, 2014.

Eleven Biotherapeutics Presents Data on Novel Protein Therapeutics for Treatment of Front and Back of Eye Diseases at ARVO 2014 Annual Meeting

Eleven Biotherapeutics Presents Data on Novel Protein Therapeutics for Treatment of Front and Back of Eye Diseases at ARVO 2014 Annual Meeting

May 6, 2014

 Clinical Data on EBI-005 Demonstrated Improvements in Signs and Symptoms in Patients with Dry Eye Disease through IL-1 Inhibition

Preclinical Data on EBI-029 Demonstrated Inhibition of IL-6 as a Validated Target for Treating Diabetic Macular Edema

Eleven Biotherapeutics Appoints Gary Sternberg, M.D., M.B.A., as Executive Vice President Corporate and Business Development

Eleven Biotherapeutics Appoints Gary Sternberg, M.D., M.B.A., as Executive Vice President Corporate and Business Development

May 5, 2014

 Industry veteran and ophthalmologist brings product licensing and business development expertise

Receptos to Deliver Scientific Presentations Regarding RPC1063 at the 2014 American Academy of Neurology (AAN) Annual Meeting

Receptos to Deliver Scientific Presentations Regarding RPC1063 at the 2014 American Academy of Neurology (AAN) Annual Meeting

April 28, 2014

SAN DIEGO, Apr 28, 2014 (GLOBE NEWSWIRE via COMTEX) --Receptos Inc. today announced that Company personnel will deliver two scientific poster presentations regarding its lead program, RPC1063, at the annual meeting of the American Academy of Neurology (AAN) in Philadelphia, PA. RPC1063 is the Company's sphingosine 1-phosphate 1 receptor (S1P1R) modulator in Phase 3 development for relapsing multiple sclerosis (RMS) and Phase 2 development for inflammatory bowel disease (IBD).

Concert Pharmaceuticals Presents Positive 48-Week Results from Phase 2 Clinical Trial of CTP-499 in Diabetic Kidney Disease

Concert Pharmaceuticals Presents Positive 48-Week Results from Phase 2 Clinical Trial of CTP-499 in Diabetic Kidney Disease

April 25, 2014

CTP-499 observed to protect against large increases in serum creatinine

CTP-499 reduced biomarkers of fibrosis  

Editas Medicine Co-founders Present Novel Methods for Improving Genome Editing Specificity in Two Nature Biotechnology Papers

Editas Medicine Co-founders Present Novel Methods for Improving Genome Editing Specificity in Two Nature Biotechnology Papers

April 25, 2014

Findings Advance Therapeutic Potential for CRISPR/Cas9 Technology

Acceleron and Celgene Announce Interim Clinical Data for Sotatercept Demonstrating Dose Dependent Increases in Hemoglobin in Patients with End Stage Renal Disease on Hemodialysis

Acceleron and Celgene Announce Interim Clinical Data for Sotatercept Demonstrating Dose Dependent Increases in Hemoglobin in Patients with End Stage Renal Disease on Hemodialysis

April 23, 2014

 CAMBRIDGE, Mass., Apr 23, 2014 (BUSINESS WIRE) -- Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that its collaboration partner, Celgene Corporation, presented interim data demonstrating dose dependent increases in hemoglobin in patients with end stage renal disease (ESRD) on hemodialysis.